Xenitra Limited’s sales rocketed over 300% in Q3 2026, driven by a $30 million contract with Rockcheck and the launch of high-margin OTC and blockchain tokenised sales units.
- Q3 sales surged to $8.3 million, up 300% from Q2
- Secured $30 million Danone offtake deal with Rockcheck Group
- Launched OTC medicine business via Hong Kong Fukang acquisition
- Introduced OPAL blockchain token with $100k initial sales
- Corporate restructuring cut fixed costs by up to 50%
Sales Velocity Returns with Nutritionals and New Divisions
Xenitra Limited (ASX:XEN) delivered a striking operational turnaround in the quarter ended 31 March 2026, with sales soaring over 300% to $8.3 million. This surge was anchored by a revitalised nutritionals business and the strategic launch of two new high-margin units: over-the-counter (OTC) medicines and a blockchain-based tokenised sales ecosystem. The company’s March sales alone topped $4 million, nearly matching the annualised sales levels of FY24 after a year of restructuring.
The nutritionals division secured a major $30 million AUD offtake agreement for Danone products with the Rockcheck Group, a Chinese B2B powerhouse. This contract runs from May 2026 to April 2027 and includes an option to extend for three more years, contingent on initial sales performance. Xenitra’s Australian subsidiary also gained authorised supplier status within Rockcheck’s conglomerate, enabling broader B2B sales channels and potential expansion of product lines under this partnership. This deal cements a reliable revenue base for the coming year and is a significant boost to the company’s sales pipeline. The $30 million contract and supplier status build on Xenitra’s ongoing work with Rockcheck, which has generated over $10 million in sales since 2023, underscoring a deepening commercial relationship $30m Danone offtake deal.
Expanding into OTC Medicines with Strategic Acquisition
Xenitra’s entry into the OTC medicine market was accelerated by acquiring Hong Kong-based Fukang, which brings a pharmaceutical wholesale license, leased premises, and established online storefronts on JD Health and Tmall. This acquisition, completed in Q3, allows Xenitra to fully operationalise its cross-border OTC medicine business targeting China’s vast market. The company has already begun resourcing this division and expects it to operate at scale by Q1 FY27, with new product launches planned for Q4. This move diversifies Xenitra’s revenue streams and taps into a higher-margin segment adjacent to its nutritionals core, leveraging Fukang’s existing logistics and digital sales ecosystem Hong Kong OTC pharmacy acquisition.
Blockchain Token Ecosystem Generates Early Sales Momentum
In a bold pivot towards digital innovation, Xenitra launched the OPAL token, a blockchain-based utility and membership token designed to drive consumer engagement and loyalty through tokenised product purchases. The first products integrated into this ecosystem are from EZZ Life Sciences, exclusively distributed by Xenitra globally. Within the first week, the OPAL token ecosystem generated over $100,000 in sales and onboarded more than 20 distributors, signalling promising early traction for this novel sales channel. The token model is structured as a self-reinforcing commercial flywheel, with rewards funded through a Token Reserve that supports marketing and sales costs, enabling rapid scaling without heavy working capital demands. This initiative aims to transform customer relationships from passive consumption to active participation, potentially creating valuable intellectual property in tokenised commerce OPAL token sales milestone.
Corporate Restructuring Cuts Costs and Streamlines Operations
Alongside top-line growth, Xenitra has aggressively reduced fixed costs, with staff expenses down 37% and administrative costs halved compared to the prior corresponding period. The company is exiting low-profit joint ventures, including winding up the 168 Express JV and negotiating the divestment of New Era JV, both currently non-trading. Headcount reductions in Australia and offshoring functions to China, combined with eliminating office and rental expenses, are on track to deliver $1 million in annualised savings. These structural improvements underpin a leaner, more focused organisation better positioned to capitalise on new growth avenues.
Cash Flow Tight but Expected to Improve with Receivables Collection
Despite the sales surge, Xenitra’s operating cash flow remained negative at -$1.33 million for the quarter, reflecting significant inventory investment of $8 million to support growth and new business launches. The company ended the quarter with $1.83 million in cash and $2 million in trade receivables, expected to be collected in Q4, which should alleviate working capital pressures. The board anticipates operating cash flow will materially improve as the OTC and tokenised sales units ramp up and extraordinary cash outflows from the quarter do not recur. Financing facilities of $1 million remain fully drawn, underscoring the need for careful cash management during this growth phase.
Chairman Anthony Noble highlighted that while the new OTC and tokenised sales divisions have yet to fully contribute to revenue, they represent transformational high-margin channels that will drive future profitability. The company’s strategic focus on FMCG markets in Asia, combined with a diversified supply chain and strong brand partnerships, forms the foundation for sustained growth. The next few quarters will be critical in converting these promising initiatives into consistent cash flow and profit.
Bottom Line?
Xenitra’s operational rebound and innovative tokenised sales model set the stage for growth, but cash flow constraints and execution risks remain key hurdles to watch.
Questions in the middle?
- Will the OPAL token ecosystem scale beyond initial distributors and sustain sales momentum?
- How quickly will the OTC medicine division contribute meaningful revenue and margins?
- Can Xenitra maintain cost discipline while expanding multiple new business units simultaneously?